表紙
市場調查報告書
商品編碼
1035520

活性藥物成分的市場研究報告。按製造商,按類型,按合成類型,按藥物類型,按治療用途,按分銷渠道 - 到 2030 年全球工業收入預測

Active Pharmaceutical Ingredient Market Research Report: By Type of Manufacturer, Type, Type of Synthesis, Type of Drug, Therapeutic Application, Distribution Channel - Global Industry Revenue Estimation to 2030

出版日期: | 出版商: Prescient & Strategic Intelligence Private Limited | 英文 454 Pages | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

2020年全球原料藥市場規模達到1843.112億美元。預計到 2030 年將達到 3.57057 億美元,在 2020 年至 2030 年的預測期內,市場預計將以 6.9% 的複合年增長率增長。

由於老年人免疫力低下,易患慢性和急性疾病,而且隨著人口的增長,需要有效的藥物,導致原料藥市場的擴大。由於 COVID-19 的流行,全球對藥品的需求正在增加。隨著患者人數的增加,醫藥產品的研發,尤其是那些旨在發現有效疫苗的產品,正變得越來越活躍。大流行病帶來的需求增加也對市場產生了積極影響。 <

本報告調查了全球原料藥市場,並提供了有關市場分析、市場吸引力和戰略分析、競爭格局、公司概況等方面的全面信息。

目錄

第一章調查背景

  • 調查目的
  • 市場定義
  • 分析期
  • 市場數據報告單位
    • 金額
  • 市場規模細分:按細分市場
    • 市場細分:按製造商類型
    • 市場細分:按類型
    • 市場細分:按合成類型
    • 市場細分:按藥物類型
    • 市場細分:按治療用途
    • 市場細分:按分銷渠道
    • 市場細分:按地區
    • 國家細分市場分析
  • 主要利益相關者

第二章調查方法

  • 二次調查
    • 付費
    • 免費
    • P & S 情報數據庫
  • 初步調查
    • 主要調查細分:按地區
    • 第一次調查細分:按行業參與者
    • 主要調查明細:按名稱
    • 主要調查的細分,按公司類型
  • 估計市場規模
  • 內部市場規模計算的研究方法
  • 數據三角剖分
  • 匯率

第 3 章執行摘要

第四章行業專家/KOL之聲

第 5 章市場指標

  • 世界人口老齡化
  • 全球醫藥市場
    • 全球醫藥市場規模
    • 全球醫藥市場細分:按地區
    • 全球銷售前 10 名的藥品
    • 全球醫藥市場主要公司市場份額分析(2019年)

第 6 章細分市場的定義

  • 按製造商類型
    • 對於內部
    • 商業
  • 按類型
    • 仿製藥原料藥
    • 創新原料藥
  • 按組合類型
    • 生物技術
    • 綜合
  • 按藥物類型
    • 處方藥
    • 非處方藥
  • 按治療用途
    • 腫瘤學
    • 抗糖尿病藥
    • 抗風濕
    • 疫苗
    • 抗病毒藥物
    • 支氣管擴張劑
    • 感覺器官
    • 抗凝劑
    • 免疫抑製劑
    • 皮膚科
    • 其他
  • 按分銷渠道
    • 離線
    • 在線

第 7 章行業展望

  • 市場動態
    • 趨勢
      • 合作與併購
      • 原料藥生產的技術進步
    • 促進因素
      • 老年人口增加
      • 慢性病發病率增加
      • 仿製藥越來越重要
      • 增長因素對市場預測的影響分析
    • 抑製器
      • 製造成本高
      • 不利的藥價管理政策
      • 嚴格的規定
      • 約束對市場預測的影響分析
  • COVID-19 對原料藥市場的影響
  • 波特五力分析
    • 買方的議價能力
    • 供應商的談判權
    • 激烈的競爭
    • 新進入者的威脅
    • 替代威脅

第八章政策法規情況

  • 北美
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第 9 章全球市場規模和預測

  • 概述
  • 市場收入:按製造商類型(2015-2030)
  • 市場收入:按類型(2015-2030)
  • 市場收入:按合成類型(2015-2030)
  • 市場收入:按藥物類型(2015-2030 年)
  • 市場收入:按治療用途(2015-2030 年)
  • 市場收入:按分銷渠道(2015-2030 年)
  • 市場收入:按地區(2015-2030 年)

第 10 章北美市場規模和預測

  • 概述
  • 市場收入:按製造商類型(2015-2030)
  • 市場收入:按類型(2015-2030)
  • 市場收入:按合成類型(2015-2030)
  • 市場收入:按藥物類型(2015-2030 年)
  • 市場收入:按治療用途(2015-2030 年)
  • 市場收入:按分銷渠道(2015-2030 年)
  • 市場收入:按國家/地區(2015-2030)

第 11 章歐洲市場規模和預測

  • 概述
  • 市場收入:按製造商類型(2015-2030)
  • 市場收入:按類型(2015-2030)
  • 市場收入:按合成類型(2015-2030)
  • 市場收入:按藥物類型(2015-2030 年)
  • 市場收入:按治療用途(2015-2030 年)
  • 市場收入:按分銷渠道(2015-2030 年)
  • 市場收入:按國家/地區(2015-2030)

第 12 章亞太市場規模及預測

  • 概述
  • 市場收入:按製造商類型(2015-2030)
  • 市場收入:按類型(2015-2030)
  • 市場收入:按合成類型(2015-2030)
  • 市場收入:按藥物類型(2015-2030 年)
  • 市場收入:按治療用途(2015-2030 年)
  • 市場收入:按分銷渠道(2015-2030 年)
  • 市場收入:按國家/地區(2015-2030)

第 13 章拉丁美洲市場規模和預測

  • 概述
  • 市場收入:按製造商類型(2015-2030)
  • 市場收入:按類型(2015-2030)
  • 市場收入:按合成類型(2015-2030)
  • 市場收入:按藥物類型(2015-2030 年)
  • 市場收入:按治療用途(2015-2030 年)
  • 市場收入:按分銷渠道(2015-2030 年)
  • 市場收入:按國家/地區(2015-2030)

第 14 章中東/非洲市場規模和預測

  • 概述
  • 市場收入:按製造商類型(2015-2030)
  • 市場收入:按類型(2015-2030)
  • 市場收入:按合成類型(2015-2030)
  • 市場收入:按藥物類型(2015-2030 年)
  • 市場收入:按治療用途(2015-2030 年)
  • 市場收入:按分銷渠道(2015-2030 年)
  • 市場收入:按國家/地區(2015-2030)

第 15 章美國市場規模和預測

  • 概述
  • 市場收入:按製造商類型(2015-2030)
  • 市場收入:按類型(2015-2030)
  • 市場收入:按合成類型(2015-2030)
  • 市場收入:按藥物類型(2015-2030 年)
  • 市場收入:按治療用途(2015-2030 年)
  • 市場收入:按分銷渠道(2015-2030 年)

第 16 章加拿大市場規模和預測

  • 概述
  • 市場收入:按製造商類型(2015-2030)
  • 市場收入:按類型(2015-2030)
  • 市場收入:按合成類型(2015-2030)
  • 市場收入:按藥物類型(2015-2030 年)
  • 市場收入:按治療用途(2015-2030 年)
  • 市場收入:按分銷渠道(2015-2030 年)

第 17 章德國市場規模和預測

  • 概述
  • 市場收入:按製造商類型(2015-2030)
  • 市場收入:按類型(2015-2030)
  • 市場收入:按合成類型(2015-2030)
  • 市場收入:按藥物類型(2015-2030 年)
  • 市場收入:按治療用途(2015-2030 年)
  • 市場收入:按分銷渠道(2015-2030 年)

第 18 章法國市場規模和預測

  • 概述
  • 市場收入:按製造商類型(2015-2030)
  • 市場收入:按類型(2015-2030)
  • 市場收入:按合成類型(2015-2030)
  • 市場收入:按藥物類型(2015-2030 年)
  • 市場收入:按治療用途(2015-2030 年)
  • 市場收入:按分銷渠道(2015-2030 年)

第 19 章英國市場規模和預測

  • 概述
  • 市場收入:按製造商類型(2015-2030)
  • 市場收入:按類型(2015-2030)
  • 市場收入:按合成類型(2015-2030)
  • 市場收入:按藥物類型(2015-2030 年)
  • 市場收入:按治療用途(2015-2030 年)
  • 市場收入:按分銷渠道(2015-2030 年)

第 20 章意大利市場規模和預測

  • 概述
  • 市場收入:按製造商類型(2015-2030)
  • 市場收入:按類型(2015-2030)
  • 市場收入:按合成類型(2015-2030)
  • 市場收入:按藥物類型(2015-2030 年)
  • 市場收入:按治療用途(2015-2030 年)
  • 市場收入:按分銷渠道(2015-2030 年)

第 21 章西班牙市場規模和預測

  • 概述
  • 市場收入:按製造商類型(2015-2030)
  • 市場收入:按類型(2015-2030)
  • 市場收入:按合成類型(2015-2030)
  • 市場收入:按藥物類型(2015-2030 年)
  • 市場收入:按治療用途(2015-2030 年)
  • 市場收入:按分銷渠道(2015-2030 年)

第 22 章日本市場規模和預測

  • 概述
  • 市場收入:按製造商類型(2015-2030)
  • 市場收入:按類型(2015-2030)
  • 市場收入:按合成類型(2015-2030)
  • 市場收入:按藥物類型(2015-2030 年)
  • 市場收入:按治療用途(2015-2030 年)
  • 市場收入:按分銷渠道(2015-2030 年)

第23章中國市場規模及預測

  • 概述
  • 市場收入:按製造商類型(2015-2030)
  • 市場收入:按類型(2015-2030)
  • 市場收入:按合成類型(2015-2030)
  • 市場收入:按藥物類型(2015-2030 年)
  • 市場收入:按治療用途(2015-2030 年)
  • 市場收入:按分銷渠道(2015-2030 年)

第 24 章印度市場規模和預測

  • 概述
  • 市場收入:按製造商類型(2015-2030)
  • 市場收入:按類型(2015-2030)
  • 市場收入:按合成類型(2015-2030)
  • 市場收入:按藥物類型(2015-2030 年)
  • 市場收入:按治療用途(2015-2030 年)
  • 市場收入:按分銷渠道(2015-2030 年)

第 25 章澳大利亞市場規模和預測

  • 概述
  • 市場收入:按製造商類型(2015-2030)
  • 市場收入:按類型(2015-2030)
  • 市場收入:按合成類型(2015-2030)
  • 市場收入:按藥物類型(2015-2030 年)
  • 市場收入:按治療用途(2015-2030 年)
  • 市場收入:按分銷渠道(2015-2030 年)

第26章韓國市場規模及預測

  • 概述
  • 市場收入:按製造商類型(2015-2030)
  • 市場收入:按類型(2015-2030)
  • 市場收入:按合成類型(2015-2030)
  • 市場收入:按藥物類型(2015-2030 年)
  • 市場收入:按治療用途(2015-2030 年)
  • 市場收入:按分銷渠道(2015-2030 年)

第 27 章巴西市場規模和預測

  • 概述
  • 市場收入:按製造商類型(2015-2030)
  • 市場收入:按類型(2015-2030)
  • 市場收入:按合成類型(2015-2030)
  • 市場收入:按藥物類型(2015-2030 年)
  • 市場收入:按治療用途(2015-2030 年)
  • 市場收入:按分銷渠道(2015-2030 年)

第 28 章墨西哥市場規模和預測

  • 概述
  • 市場收入:按製造商類型(2015-2030)
  • 市場收入:按類型(2015-2030)
  • 市場收入:按合成類型(2015-2030)
  • 市場收入:按藥物類型(2015-2030 年)
  • 市場收入:按治療用途(2015-2030 年)
  • 市場收入:按分銷渠道(2015-2030 年)

第 29 章沙特阿拉伯市場規模和預測

  • 概述
  • 市場收入:按製造商類型(2015-2030)
  • 市場收入:按類型(2015-2030)
  • 市場收入:按合成類型(2015-2030)
  • 市場收入:按藥物類型(2015-2030 年)
  • 市場收入:按治療用途(2015-2030 年)
  • 市場收入:按分銷渠道(2015-2030 年)

第 30 章阿拉伯聯合酋長國市場規模和預測

  • 概述
  • 市場收入:按製造商類型(2015-2030)
  • 市場收入:按類型(2015-2030)
  • 市場收入:按合成類型(2015-2030)
  • 市場收入:按藥物類型(2015-2030 年)
  • 市場收入:按治療用途(2015-2030 年)
  • 市場收入:按分銷渠道(2015-2030 年)

第31章競爭形勢

  • 主要原料藥
  • 各大公司利潤對比
  • 世界戰略發展
    • 合作夥伴關係
    • 產品發佈和擴展
    • 併購

第32章公司簡介

  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Teva Pharmaceutical Industries Limited
  • Aurobindo Pharma Limited
  • Novartis AG
  • Pfizer Inc.
  • Bristol-Myers Squibb Company
  • Glenmark Life Sciences Limited
  • Johnson & Johnson
  • Merck & Co. Inc.
  • AbbVie Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Amneal Pharmaceuticals Inc.
  • AstraZeneca plc
  • Sun Pharmaceutical Industries Ltd.
  • Alkem Laboratories Limited
  • Mylan N.V.
  • Lupin Limited
  • STADA Arzneimittel AG
  • Mallinckrodt plc
  • Glenmark Life Sciences Limited
  • MSN Laboratories Pvt. Ltd.

第33章附錄

  • 來源和參考資料
  • 相關報導
目錄
Product Code: LS12190

The global active pharmaceutical ingredient market value stood at $184,311.2 million in 2020, and it is expected to surge to $357,005.7 million by 2030, demonstrating a CAGR of 6.9% from 2021 to 2030.

The major factors fueling the demand for these ingredients are:

  • Mushrooming Geriatric Population: According to the World Health Organization (WHO), the surge in the average life expectancy in recent years has caused a sharp rise in the population of older people. As per the World Population Ageing 2020 report published by the United Nations Department of Economic and Social Affairs (UNDESA), the population of people aged 65 years and above will rise from 727 million in 2020 to more than 1.5 billion by 2050. As geriatric people are vulnerable to chronic and acute illnesses due to their weak immune systems, their soaring population is driving the requirement for effective drugs, which is consequently fueling the expansion of the API market.
  • Increasing Occurrence of Chronic Diseases: With people following sedentary lifestyles and the prevalence of obesity increasing, the incidence of various chronic diseases, such as diabetes, is soaring across the globe. According to the WHO, 422 million people are currently living with it and the disease claims 1.6 million lives every year. Being a long-term disease, patients require constant medication, particularly insulin.

The COVID-19 pandemic has amplified the worldwide demand for pharmaceutical products. Due to the increasing number of patients, drug research and development activities, especially those aimed at finding an effective vaccine, have surged. Additionally, the API market has been positively impacted by the rising demand for such products during the pandemic. For instance, the Pharmaceutical Export Promotion Council (PHARMEXCIL) of India recorded a significant increase in the cost of penicillin, one of the most-well-known antibiotic APIs, from $6.16 per unit in January 2020 to $8.69 per unit in just one month.

In the past, the prescription drug category contributed the higher revenue to the API market, under the type of drug segment. The requirement for prescription drugs for managing complex chronic illnesses is rising across the world, thereby propelling the consumption of associated active ingredients.

The oncology category dominated the API market during the last few years, within the therapeutic application segment. The high incidence of cancer is resulting in the rising requirement for highly potent APIs (HPAPIs). As per the American Cancer Society, by 2021-end, nearly 1.9 million new cases of cancer and 608,570 related deaths will be reported in the U.S. Similarly, as per the WHO, there were 2,003,789 cases of various types of cancers in Southeast Asia in 2018. Moreover, the disease claimed the lives of 1,336,026 people in the same year.

Geographically, North America is predicted to dominate the API market in the forthcoming years due to the rising prevalence of and awareness on chronic and lifestyle-associated illnesses, surging focus of governments on generic drugs, soaring requirement for specialty drugs and biologics, rapid technological advancements, and increasing number of pharmaceutical R&D activities in the region. For instance, as per the Centers for Disease Control and Prevention (CDC), in 2018, chronic illnesses cost $3.5 trillion to the U.S. healthcare system.

The major players operating in the global API market are: Dr. Reddy's Laboratories Ltd., Cipla Ltd., Novartis AG, Teva Pharmaceutical Industries Limited, Takeda Pharmaceutical Company Limited, Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Alkem Laboratories Limited, MSN Laboratories Pvt. Ltd., AstraZeneca plc, GlaxoSmithKline plc, Mallinckrodt plc, Sun Pharmaceutical Industries Ltd., STADA Arzneimittel AG, Lupin Limited, Mylan N.V., Amneal Pharmaceuticals Inc., AbbVie Inc., Johnson & Johnson, Merck & Co. Inc., Glenmark Life Sciences Limited, Eli Lilly and Company, and Sanofi.

Table of Contents

Chapter 1. Research Background

  • 1.1 Research Objectives
  • 1.2 Market Definition
  • 1.3 Analysis Period
  • 1.4 Market Data Reporting Unit
    • 1.4.1 Value
  • 1.5 Market Size Breakdown by Segment
    • 1.5.1 Market Segmentation by Type of Manufacturer
    • 1.5.2 Market Segmentation by Type
    • 1.5.3 Market Segmentation by Type of Synthesis
    • 1.5.4 Market Segmentation by Type of Drug
    • 1.5.5 Market Segmentation by Therapeutic Application
    • 1.5.6 Market Segmentation by Distribution Channel
    • 1.5.7 Market Segmentation by Region
    • 1.5.8 Market Segment Analysis of Countries
  • 1.6 Key Stakeholders

Chapter 2. Research Methodology

  • 2.1 Secondary Research
    • 2.1.1 Paid
    • 2.1.2 Unpaid
    • 2.1.3 P&S Intelligence Database
  • 2.2 Primary Research
    • 2.2.1 Breakdown of Primary Research, by Region
    • 2.2.2 Breakdown of Primary Research, by Industry Participant
    • 2.2.3 Breakdown of Primary Research, by Designation
    • 2.2.4 Breakdown of Primary Research, by Company Type
  • 2.3 Market Size Estimation
  • 2.4 Methodology for Captive Market Size Calculation
  • 2.5 Data Triangulation
  • 2.6 Currency Conversion Rates

Chapter 3. Executive Summary

Chapter 4. Voice of Industry Experts/KOLs

Chapter 5. Market Indicators

  • 5.1 World Aging Population
  • 5.2 Global Pharmaceutical Market
    • 5.2.1 Global Pharmaceutical Market Size
    • 5.2.2 Global Pharmaceutical Market Breakdown, By Geography
    • 5.2.3 Global Top 10 Selling Drugs
    • 5.2.4 Global Pharmaceutical Market Share Analysis of Key Players (2019)

Chapter 6. Definition of Market Segments

  • 6.1 By Type of Manufacturer
    • 6.1.1 Captive
    • 6.1.2 Merchant
  • 6.2 By Type
    • 6.2.1 Generic APIs
    • 6.2.2 Innovative APIs
  • 6.3 By Type of Synthesis
    • 6.3.1 Biotech
    • 6.3.2 Synthetic
  • 6.4 By Type of Drug
    • 6.4.1 Prescription Drugs
    • 6.4.2 OTC Drugs
  • 6.5 By Therapeutic Application
    • 6.5.1 Oncology
    • 6.5.2 Anti-diabetics
    • 6.5.3 Anti-rheumatics
    • 6.5.4 Vaccines
    • 6.5.5 Antiviral
    • 6.5.6 Bronchodilators
    • 6.5.7 Sensory Organs
    • 6.5.8 Anti-coagulants
    • 6.5.9 Immunosuppressants
    • 6.5.10 Dermatologicals
    • 6.5.11 Others
  • 6.6 By Distribution Channel
    • 6.6.1 Offline
    • 6.6.2 Online

Chapter 7. Industry Outlook

  • 7.1 Market Dynamics
    • 7.1.1 Trends
      • 7.1.1.1 Partnerships and mergers & acquisitions
      • 7.1.1.2 Technological advancement in API manufacturing
    • 7.1.2 Drivers
      • 7.1.2.1 Rising geriatric population
      • 7.1.2.2 Increasing incidence of chronic diseases
      • 7.1.2.3 Growing importance of generics
      • 7.1.2.4 Impact analysis of drivers on market forecast
    • 7.1.3 Restraints
      • 7.1.3.1 High manufacturing costs
      • 7.1.3.2 Unfavorable drug price control policies
      • 7.1.3.3 Stringent regulations
      • 7.1.3.4 Impact analysis of restraints on market forecast
  • 7.2 Impact of COVID-19 on API Market
  • 7.3 Porter's Five Forces Analysis
    • 7.3.1 Bargaining Power of Buyers
    • 7.3.2 Bargaining Power of Suppliers
    • 7.3.3 Intensity of Rivalry
    • 7.3.4 Threat of New Entrants
    • 7.3.5 Threat of Substitutes

Chapter 8. Policy and Regulatory Landscape

  • 8.1 North America
  • 8.2 Europe
  • 8.3 APAC
  • 8.4 LATAM
  • 8.5 MEA

Chapter 9. Global Market Size and Forecast

  • 9.1 Overview
  • 9.2 Market Revenue, by Type of Manufacturer (2015-2030)
  • 9.3 Market Revenue, by Type (2015-2030)
  • 9.4 Market Revenue, by Type of Synthesis (2015-2030)
  • 9.5 Market Revenue, by Type of Drug (2015-2030)
  • 9.6 Market Revenue, by Therapeutic Application (2015-2030)
  • 9.7 Market Revenue, by Distribution Channel (2015-2030)
  • 9.8 Market Revenue, by Region (2015-2030)

Chapter 10. North America Market Size and Forecast

  • 10.1 Overview
  • 10.2 Market Revenue, by Type of Manufacturer (2015-2030)
  • 10.3 Market Revenue, by Type (2015-2030)
  • 10.4 Market Revenue, by Type of Synthesis (2015-2030)
  • 10.5 Market Revenue, by Type of Drug (2015-2030)
  • 10.6 Market Revenue, by Therapeutic Application (2015-2030)
  • 10.7 Market Revenue, by Distribution Channel (2015-2030)
  • 10.8 Market Revenue, by Country (2015-2030)

Chapter 11. Europe Market Size and Forecast

  • 11.1 Overview
  • 11.2 Market Revenue, by Type of Manufacturer (2015-2030)
  • 11.3 Market Revenue, by Type (2015-2030)
  • 11.4 Market Revenue, by Type of Synthesis (2015-2030)
  • 11.5 Market Revenue, by Type of Drug (2015-2030)
  • 11.6 Market Revenue, by Therapeutic Application (2015-2030)
  • 11.7 Market Revenue, by Distribution Channel (2015-2030)
  • 11.8 Market Revenue, by Country (2015-2030)

Chapter 12. APAC Market Size and Forecast

  • 12.1 Overview
  • 12.2 Market Revenue, by Type of Manufacturer (2015-2030)
  • 12.3 Market Revenue, by Type (2015-2030)
  • 12.4 Market Revenue, by Type of Synthesis (2015-2030)
  • 12.5 Market Revenue, by Type of Drug (2015-2030)
  • 12.6 Market Revenue, by Therapeutic Application (2015-2030)
  • 12.7 Market Revenue, by Distribution Channel (2015-2030)
  • 12.8 Market Revenue, by Country (2015-2030)

Chapter 13. LATAM Market Size and Forecast

  • 13.1 Overview
  • 13.2 Market Revenue, by Type of Manufacturer (2015-2030)
  • 13.3 Market Revenue, by Type (2015-2030)
  • 13.4 Market Revenue, by Type of Synthesis (2015-2030)
  • 13.5 Market Revenue, by Type of Drug (2015-2030)
  • 13.6 Market Revenue, by Therapeutic Application (2015-2030)
  • 13.7 Market Revenue, by Distribution Channel (2015-2030)
  • 13.8 Market Revenue, by Country (2015-2030)

Chapter 14. MEA Market Size and Forecast

  • 14.1 Overview
  • 14.2 Market Revenue, by Type of Manufacturer (2015-2030)
  • 14.3 Market Revenue, by Type (2015-2030)
  • 14.4 Market Revenue, by Type of Synthesis (2015-2030)
  • 14.5 Market Revenue, by Type of Drug (2015-2030)
  • 14.6 Market Revenue, by Therapeutic Application (2015-2030)
  • 14.7 Market Revenue, by Distribution Channel (2015-2030)
  • 14.8 Market Revenue, by Country (2015-2030)

Chapter 15. U.S. Market Size and Forecast

  • 15.1 Overview
  • 15.2 Market Revenue, by Type of Manufacturer (2015-2030)
  • 15.3 Market Revenue, by Type (2015-2030)
  • 15.4 Market Revenue, by Type of Synthesis (2015-2030)
  • 15.5 Market Revenue, by Type of Drug (2015-2030)
  • 15.6 Market Revenue, by Therapeutic Application (2015-2030)
  • 15.7 Market Revenue, by Distribution Channel (2015-2030)

Chapter 16. Canada Market Size and Forecast

  • 16.1 Overview
  • 16.2 Market Revenue, by Type of Manufacturer (2015-2030)
  • 16.3 Market Revenue, by Type (2015-2030)
  • 16.4 Market Revenue, by Type of Synthesis (2015-2030)
  • 16.5 Market Revenue, by Type of Drug (2015-2030)
  • 16.6 Market Revenue, by Therapeutic Application (2015-2030)
  • 16.7 Market Revenue, by Distribution Channel (2015-2030)

Chapter 17. Germany Market Size and Forecast

  • 17.1 Overview
  • 17.2 Market Revenue, by Type of Manufacturer (2015-2030)
  • 17.3 Market Revenue, by Type (2015-2030)
  • 17.4 Market Revenue, by Type of Synthesis (2015-2030)
  • 17.5 Market Revenue, by Type of Drug (2015-2030)
  • 17.6 Market Revenue, by Therapeutic Application (2015-2030)
  • 17.7 Market Revenue, by Distribution Channel (2015-2030)

Chapter 18. France Market Size and Forecast

  • 18.1 Overview
  • 18.2 Market Revenue, by Type of Manufacturer (2015-2030)
  • 18.3 Market Revenue, by Type (2015-2030)
  • 18.4 Market Revenue, by Type of Synthesis (2015-2030)
  • 18.5 Market Revenue, by Type of Drug (2015-2030)
  • 18.6 Market Revenue, by Therapeutic Application (2015-2030)
  • 18.7 Market Revenue, by Distribution Channel (2015-2030)

Chapter 19. U.K. Market Size and Forecast

  • 19.1 Overview
  • 19.2 Market Revenue, by Type of Manufacturer (2015-2030)
  • 19.3 Market Revenue, by Type (2015-2030)
  • 19.4 Market Revenue, by Type of Synthesis (2015-2030)
  • 19.5 Market Revenue, by Type of Drug (2015-2030)
  • 19.6 Market Revenue, by Therapeutic Application (2015-2030)
  • 19.7 Market Revenue, by Distribution Channel (2015-2030)

Chapter 20. Italy Market Size and Forecast

  • 20.1 Overview
  • 20.2 Market Revenue, by Type of Manufacturer (2015-2030)
  • 20.3 Market Revenue, by Type (2015-2030)
  • 20.4 Market Revenue, by Type of Synthesis (2015-2030)
  • 20.5 Market Revenue, by Type of Drug (2015-2030)
  • 20.6 Market Revenue, by Therapeutic Application (2015-2030)
  • 20.7 Market Revenue, by Distribution Channel (2015-2030)

Chapter 21. Spain Market Size and Forecast

  • 21.1 Overview
  • 21.2 Market Revenue, by Type of Manufacturer (2015-2030)
  • 21.3 Market Revenue, by Type (2015-2030)
  • 21.4 Market Revenue, by Type of Synthesis (2015-2030)
  • 21.5 Market Revenue, by Type of Drug (2015-2030)
  • 21.6 Market Revenue, by Therapeutic Application (2015-2030)
  • 21.7 Market Revenue, by Distribution Channel (2015-2030)

Chapter 22. Japan Market Size and Forecast

  • 22.1 Overview
  • 22.2 Market Revenue, by Type of Manufacturer (2015-2030)
  • 22.3 Market Revenue, by Type (2015-2030)
  • 22.4 Market Revenue, by Type of Synthesis (2015-2030)
  • 22.5 Market Revenue, by Type of Drug (2015-2030)
  • 22.6 Market Revenue, by Therapeutic Application (2015-2030)
  • 22.7 Market Revenue, by Distribution Channel (2015-2030)

Chapter 23. China Market Size and Forecast

  • 23.1 Overview
  • 23.2 Market Revenue, by Type of Manufacturer (2015-2030)
  • 23.3 Market Revenue, by Type (2015-2030)
  • 23.4 Market Revenue, by Type of Synthesis (2015-2030)
  • 23.5 Market Revenue, by Type of Drug (2015-2030)
  • 23.6 Market Revenue, by Therapeutic Application (2015-2030)
  • 23.7 Market Revenue, by Distribution Channel (2015-2030)

Chapter 24. India Market Size and Forecast

  • 24.1 Overview
  • 24.2 Market Revenue, by Type of Manufacturer (2015-2030)
  • 24.3 Market Revenue, by Type (2015-2030)
  • 24.4 Market Revenue, by Type of Synthesis (2015-2030)
  • 24.5 Market Revenue, by Type of Drug (2015-2030)
  • 24.6 Market Revenue, by Therapeutic Application (2015-2030)
  • 24.7 Market Revenue, by Distribution Channel (2015-2030)

Chapter 25. Australia Market Size and Forecast

  • 25.1 Overview
  • 25.2 Market Revenue, by Type of Manufacturer (2015-2030)
  • 25.3 Market Revenue, by Type (2015-2030)
  • 25.4 Market Revenue, by Type of Synthesis (2015-2030)
  • 25.5 Market Revenue, by Type of Drug (2015-2030)
  • 25.6 Market Revenue, by Therapeutic Application (2015-2030)
  • 25.7 Market Revenue, by Distribution Channel (2015-2030)

Chapter 26. South Korea Market Size and Forecast

  • 26.1 Overview
  • 26.2 Market Revenue, by Type of Manufacturer (2015-2030)
  • 26.3 Market Revenue, by Type (2015-2030)
  • 26.4 Market Revenue, by Type of Synthesis (2015-2030)
  • 26.5 Market Revenue, by Type of Drug (2015-2030)
  • 26.6 Market Revenue, by Therapeutic Application (2015-2030)
  • 26.7 Market Revenue, by Distribution Channel (2015-2030)

Chapter 27. Brazil Market Size and Forecast

  • 27.1 Overview
  • 27.2 Market Revenue, by Type of Manufacturer (2015-2030)
  • 27.3 Market Revenue, by Type (2015-2030)
  • 27.4 Market Revenue, by Type of Synthesis (2015-2030)
  • 27.5 Market Revenue, by Type of Drug (2015-2030)
  • 27.6 Market Revenue, by Therapeutic Application (2015-2030)
  • 27.7 Market Revenue, by Distribution Channel (2015-2030)

Chapter 28. Mexico Market Size and Forecast

  • 28.1 Overview
  • 28.2 Market Revenue, by Type of Manufacturer (2015-2030)
  • 28.3 Market Revenue, by Type (2015-2030)
  • 28.4 Market Revenue, by Type of Synthesis (2015-2030)
  • 28.5 Market Revenue, by Type of Drug (2015-2030)
  • 28.6 Market Revenue, by Therapeutic Application (2015-2030)
  • 28.7 Market Revenue, by Distribution Channel (2015-2030)

Chapter 29. Saudi Arabia Market Size and Forecast

  • 29.1 Overview
  • 29.2 Market Revenue, by Type of Manufacturer (2015-2030)
  • 29.3 Market Revenue, by Type (2015-2030)
  • 29.4 Market Revenue, by Type of Synthesis (2015-2030)
  • 29.5 Market Revenue, by Type of Drug (2015-2030)
  • 29.6 Market Revenue, by Therapeutic Application (2015-2030)
  • 29.7 Market Revenue, by Distribution Channel (2015-2030)

Chapter 30. U.A.E. Market Size and Forecast

  • 30.1 Overview
  • 30.2 Market Revenue, by Type of Manufacturer (2015-2030)
  • 30.3 Market Revenue, by Type (2015-2030)
  • 30.4 Market Revenue, by Type of Synthesis (2015-2030)
  • 30.5 Market Revenue, by Type of Drug (2015-2030)
  • 30.6 Market Revenue, by Therapeutic Application (2015-2030)
  • 30.7 Market Revenue, by Distribution Channel (2015-2030)

Chapter 31. Competitive Landscape

  • 31.1 Major API Molecules
  • 31.2 Revenue Comparison of Major Players
  • 31.3 Global Strategic Developments
    • 31.3.1 Partnerships
    • 31.3.2 Product Launches and Expansion
    • 31.3.3 Mergers & Acquisitions

Chapter 32. Company Profiles

  • 32.1 Cipla Ltd.
    • 32.1.1 Business Overview
    • 32.1.2 Product and Service Offerings
    • 32.1.3 Key Financial Summary
  • 32.2 Dr. Reddy's Laboratories Ltd.
    • 32.2.1 Business Overview
    • 32.2.2 Product and Service Offerings
    • 32.2.3 Key Financial Summary
  • 32.3 Teva Pharmaceutical Industries Limited
    • 32.3.1 Business Overview
    • 32.3.2 Product and Service Offerings
    • 32.3.3 Key Financial Summary
  • 32.4 Aurobindo Pharma Limited
    • 32.4.1 Business Overview
    • 32.4.2 Product and Service Offerings
    • 32.4.3 Key Financial Summary
  • 32.5 Novartis AG
    • 32.5.1 Business Overview
    • 32.5.2 Product and Service Offerings
    • 32.5.3 Key Financial Summary
  • 32.6 Pfizer Inc.
    • 32.6.1 Business Overview
    • 32.6.2 Product and Service Offerings
    • 32.6.3 Key Financial Summary
  • 32.7 Bristol-Myers Squibb Company
    • 32.7.1 Business Overview
    • 32.7.2 Product and Service Offerings
    • 32.7.3 Key Financial Summary
  • 32.8 Glenmark Life Sciences Limited
    • 32.8.1 Business Overview
    • 32.8.2 Product and Service Offerings
    • 32.8.3 Key Financial Summary
  • 32.9 Johnson & Johnson
    • 32.9.1 Business Overview
    • 32.9.2 Product and Service Offerings
    • 32.9.3 Key Financial Summary
  • 32.10 Merck & Co. Inc.
    • 32.10.1 Business Overview
    • 32.10.2 Product and Service Offerings
    • 32.10.3 Key Financial Summary
  • 32.11 AbbVie Inc.
    • 32.11.1 Business Overview
    • 32.11.2 Product and Service Offerings
    • 32.11.3 Key Financial Summary
  • 32.12 Eli Lilly and Company
    • 32.12.1 Business Overview
    • 32.12.2 Product and Service Offerings
    • 32.12.3 Key Financial Summary
  • 32.13 GlaxoSmithKline plc
    • 32.13.1 Business Overview
    • 32.13.2 Product and Service Offerings
    • 32.13.3 Key Financial Summary
  • 32.14 Sanofi
    • 32.14.1 Business Overview
    • 32.14.2 Product and Service Offerings
    • 32.14.3 Key Financial Summary
  • 32.15 Takeda Pharmaceutical Company Limited
    • 32.15.1 Business Overview
    • 32.15.2 Product and Service Offerings
    • 32.15.3 Key Financial Summary
  • 32.16 Amneal Pharmaceuticals Inc.
    • 32.16.1 Business Overview
    • 32.16.2 Product and Service Offerings
    • 32.16.3 Key Financial Summary
  • 32.17 AstraZeneca plc
    • 32.17.1 Business Overview
    • 32.17.2 Product and Service Offerings
    • 32.17.3 Key Financial Summary
  • 32.18 Sun Pharmaceutical Industries Ltd.
    • 32.18.1 Business Overview
    • 32.18.2 Product and Service Offerings
    • 32.18.3 Key Financial Summary
  • 32.19 Alkem Laboratories Limited
    • 32.19.1 Business Overview
    • 32.19.2 Product and Service Offerings
    • 32.19.3 Key Financial Summary
  • 32.20 Mylan N.V.
    • 32.20.1 Business Overview
    • 32.20.2 Product and Service Offerings
    • 32.20.3 Key Financial Summary
  • 32.21 Lupin Limited
    • 32.21.1 Business Overview
    • 32.21.2 Product and Service Offerings
    • 32.21.3 Key Financial Summary
  • 32.22 STADA Arzneimittel AG
    • 32.22.1 Business Overview
    • 32.22.2 Product and Service Offerings
    • 32.22.3 Key Financial Summary
  • 32.23 Mallinckrodt plc
    • 32.23.1 Business Overview
    • 32.23.2 Product and Service Offerings
    • 32.23.3 Key Financial Summary
  • 32.24 Glenmark Life Sciences Limited
    • 32.24.1 Business Overview
    • 32.24.2 Product and Service Offerings
    • 32.24.3 Key Financial Summary
  • 32.25 MSN Laboratories Pvt. Ltd.
    • 32.25.1 Business Overview
    • 32.25.2 Product and Service Offerings

Chapter 33. Appendix

  • 33.1 Sources and References
  • 33.2 Related Reports